期刊文献+

吉西他滨联合奥沙利铂二线治疗复发难治性卵巢癌的临床疗效观察

Experimental Study of Gemcitabine-oxaliplatin Combination for Recrudescent or Intractable Ovarian Cancer
下载PDF
导出
摘要 目的 观察吉西他滨联合奥沙利铂治疗复发难治性卵巢癌,临床影像学及肿瘤标志物CA125的变化情况,评价该化疗方案的临床疗效.方法22例复发难治性卵巢癌患者采用吉西他滨联合奥沙利铂方案进行化疗两个周期,化疗前后检测外周血中的CA125,并观察影像学变化情况.结果患者化疗后CA125降低,有统计学意义;影像学上比较肿块退缩情况,取得了较高的有效率.结论 吉西他滨联合奥沙利铂方案二线治疗复发难治性卵巢癌有较好的治疗疗效,副反应可耐受. Objective To observe lhe change of CA125 in the peripheal blood and clinical iconograph',, in recrudescent or intrac- able owtrian cancer before and alter chemotherapy of gemcilabine and oxaliplalin, and observe lhe clinical curalive effect of lhe chemothera- py. Methods Twenty-two patients with recrudescent or intractable owu'ian cancer were treated with chemotherapy of gemcitabine and oxali- platin. The change of CA125 and clinical iconography were checked before and after two period chemotherapy. Results The concentrations of CAI25 were significantly decreased after treatment,there was statistical diterence. There were a ifighly effective rate by comparing the tumour befk)re and after trealment. Conclusion Gemcitabine combine with oxaliplatin are extremely effective for recrudescent or intraclable ovarian cancer, and the side effect is not serious.
出处 《潍坊医学院学报》 2011年第4期255-256,共2页 Acta Academiae Medicinae Weifang
关键词 吉西他滨 奥沙利铂 卵巢肿瘤 CA125 Gemcitabine Oxaliplatin Ovarian cancer CA125
  • 相关文献

参考文献5

  • 1包乐纹,王国兴,张燮良.卵巢癌的二线化疗[J].中国肿瘤临床,2004,31(2):118-122. 被引量:10
  • 2Palmer C,Duan X.Systematic evaluation of candidate blood markers for detecting ovarian cancer[J].PLos 0ne,2008,3 (7):2633.
  • 3Micha JP,Goldstein BH.Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma[J].Oncology,2006,71 (1-2):49 - 53.
  • 4吕卫国,叶大风.奥沙利铂及其在卵巢癌治疗中的应用[J].国外医学(妇产科学分册),2001,28(2):94-97. 被引量:4
  • 5Harnett P,Buck M.Phase Ⅱ study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer:an australian and new zealand gynaecological oncology group study[J].Int J Gynecol Cancer,2007,17(2):359 -366.

二级参考文献68

  • 1[1]Memarzadeh S, Berek JS. Advances in the management of epithelial ovarian cancer[J]. J Repord Med, 2001, 46(7): 621~629
  • 2[2]Bodurka-Bevers D, Sun CC, Gershenson MD. Pharmacoeconomic considerations in treating ovarian cancer [J]. Pharmacoeconomics, 2000, 17(2): 133~150
  • 3[3]Landis SH, Murray T, Bolden S, et al. Cancer statistics1 1998[J]. CA Cancer J Clin, 1998, 48(6): 3~29
  • 4[4]Nahhas WA. Ovarian cancer. Current outlook on the deadly disease [J]. Postgrad Med, 1997, 102(3): 112~120
  • 5[5]Markman M, Hoskins W. Responses to "salvage" chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population[J]. J Clin Oncol, 1992,10(4):513~514
  • 6[6]Cremers GJ. Bolis G, Gone M, et al. Topetecan, an active drug in the second-line treatment of epithelial ovarian cancer,results of a large European phase 2 study [J]. J Clin Oncol,1996, 14(12): 3056~3061
  • 7[7]Thigpen JT, Blessing JA, Ball H, et al. Phase Ⅱ trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study[J]. J Clin Oncol, 1994, 12(9): 1748~1753
  • 8[8]Coeffic D. Paclitaxel, Topetecan and Cisplantin combination chemotherapy in advanced ovarian cancer [J]. Proc Annu Meeting Soc Gynecol Oncol, 2000, 19:1601
  • 9[9]Hall JB, Higgins RV, Naumaun RW. Phase 2 study of Topotecan and Cisplatin combination chemotherapy in stage 3/4 of recurrent endonetnial cancer[J]. Proc Annu Meeting Soc Gynecol Oncol, 2000, 19:1618
  • 10[10]Gore ME, Fryatt I, Wiltshaw E, et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds [J]. Gynecol Oncol,1990, 36(2): 207~211

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部